Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response

Chun-Lan Zhuanga, Zhi-Jie Linb, Zhao-Feng Bic, Ling-Xian Qia, Fang-Fang Huia, Xiao-Hui Liua, Bi-Zhen Linb, Ying-Ying Sun, Hui-Rong Panb, Tian-Ying Zhanga, Shou-Jie Huanga, Yue-Mei Huia, You-Lin Qiaod, Feng-Cai Zhub, Ting Wua, Jun Zhanga and Ning-Shao Xia

aState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Stratoll Collaborative Innovation Center of Biomedicine and Pharmaceutics, School of Public Health, Xiamen University, Xiamen, People’s Republic of China; bXiamen Innovax Biotech CO., Ltd., Xiamen, People’s Republic of China; cJiangsu Provincial Center for Disease Control and Prevention, Public Health Research Institute of Jiangsu Province, Nanjing, People’s Republic of China; dChinese Academy of Medical Sciences/Peking Union Medical College School of Population Medicine and Public Health, Beijing, People’s Republic of China

ABSTRACT
Concerns about vaccine safety are an important reason for vaccine hesitancy, however, limited information is available on whether common adverse reactions following vaccination affect the immune response. Data from three clinical trials of recombinant vaccines were used in this post hoc analysis to assess the correlation between inflammation-related solicited adverse reactions (ISARs, including local pain, redness, swelling or induration and systematic fever) and immune responses after vaccination. In the phase III trial of the bivalent HPV-16/18 vaccine (Cecolin™), the geometric mean concentrations (GMCs) for IgG anti-HPV-16 and -18 (P<0.001) were significantly higher in participants with any ISAR following vaccination than in those without an ISAR. Local pain, induration, swelling and systemic fever were significantly correlated with higher GMCs for IgG anti-HPV-16 and/or anti-HPV-18, respectively. Furthermore, the analyses of the immunogenicity bridging study of Cecolin™ and the phase III trial of a hepatitis E vaccine yielded similar results. Based on these results, we built a scoring model to quantify the inflammation reactions and found that the high score of ISAR indicates the strong vaccine-induced antibody level. In conclusion, this study suggests inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response.

ARTICLE HISTORY
Received 14 October 2020; Revised 5 February 2021; Accepted 12 February 2021

KEYWORDS
Inflammation; adverse reaction; recombinant vaccine; immune response; antibody; vaccine hesitancy

Introduction
Vaccines are widely recognized as one of the greatest public health successes of the last century, significantly reducing morbidity and mortality from a variety of bacterial and viral infections. However, vaccine hesitancy, especially concerns about vaccine safety or adverse reactions, impedes the implementation of vaccines such as the human papillomavirus (HPV) vaccine [1–3] and measles-containing vaccine [4,5]. Currently, some innovative candidate vaccines against coronavirus disease 2019 (COVID-19) showed high immunogenicity in their early phase clinical trials [6,7], however the accompanied high incidence of moderate to severe adverse reactions makes a shadow on people’s compliance in the future implementation. Unveiling the scientific basis of adverse reactions is urgently needed to help understand mechanism of vaccines and counter vaccine hesitancy.

The different antigens or adjuvants included in vaccines differ in their mode of action and ability to stimulate the immune system [8,9]. Regardless of the mode, inflammatory responses, which are one of the biological bases for adverse reactions, are also thought to be essential for the development of adaptive immunity. A prime example is the high incidence of febrile reactions and sufficient antibody responses in young children compared with poor immunogenicity and low reactogenicity in adults after receiving an alum-adjuvanted H5N1 whole virion-inactivated vaccine [10]. The Bacillus Calmette Guerin (BCG) scar, a permanent scar resulting from acute localized inflammation through intradermal injection, has proven to be the signal of successful vaccination [11,12].
Reactogenicity represents the physical manifestation of the inflammatory response to vaccination and can include injection-site pain, redness, swelling or induration, as well as systemic symptoms such as fever [13]. These symptoms are also the most common transient adverse reactions following clinical vaccination [14–16]. Although it is a long tale that the stronger reactivity of a vaccine usually denotes a stronger immune response [17–20], few straightforward data from large-scale human trials was reported previously.

In this study, we aimed to explore the relationship between adverse reactions that may be caused by inflammation and immune responses following vaccinations on the basis of data from clinical trials of recombinant HPV and hepatitis E virus (HEV) vaccines. Furthermore, we attempted to build a simple model to quantify adverse reactions, which can be an approach to hierarchically assess individual levels of inflammatory responses after vaccination.

Materials and methods

Study design and data sources

The data used in this study were from three published clinical trials of two different recombinant vaccines. We explored a primary study, a multicenter, randomized, double-blind, phase III trial of a novel *Escherichia coli*-produced bivalent HPV-16/18 vaccine (Cecolin*) involving females aged 18–45 years (NCT01735006) [21]. We further verified key findings in two other trials, including an immunogenicity bridging study of Cecolin* involving females aged 9–26 years (NCT02562508) [22] and the reactogenicity subset of a large-scale, randomized, double-blind, placebo-controlled, phase III trial of the HEV vaccine (Hecolin*) involving males and females aged 16–65 years (NCT01014845) [23]. All studies were approved by the Independent Ethics Committee (the phase III trial of Cecolin*:12-72/606, 2020-48, 2012044, IRB00001594; the immunogenicity bridging study of Cecolin*: JSK2015-A010-02; the phase III trial of Hecolin*: no ethics committee protocol number available due to the imperfect ethical review system at the time) and undertaken according to Good Clinical Practice.

Vaccines

Both licensed vaccines were recombinant vaccines manufactured by Xiamen Innovax, Xiamen, China, as described previously [21–24]. The bivalent HPV-16/18 vaccine (Cecolin*) is a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 Virus Like Particles (VLPs) of HPV-16 and HPV-18 expressed in *E. coli* [25–27]. The formulation comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs suspended in 0.5 ml of buffered saline containing 208 μg of aluminum adjuvant. In the phase III trial, women in the test group were randomly vaccinated with three batches of the HPV vaccine (Lot 1: B20120404; Lot 2: B20120405; and Lot 3: B20120506), and in the immunogenicity bridging study, participants were vaccinated with the same batch of the HPV vaccine (Lot: B20141201). The HEV 239 vaccine (Hecolin*) contains 30 μg of the purified antigen adsorbed to 280 μg aluminum adjuvant suspended in 0.5 ml buffered saline [28,29].

Safety data collection

Both vaccines were administered intramuscularly at day 0, month 1 and 6. The participants were requested to stay for at least 30 mins after each vaccination, and any adverse reactions observed were documented by the investigators. All the participants were trained to record adverse events (AEs), concomitant medications and concomitant vaccinations occurring within 1 month after each injection on diary cards, and the investigators followed the participants twice in 7 days after each vaccination by visiting households or making phone calls to ensure the integrity of records. The AE documents contained the time of occurrence, duration and severity that followed guiding principles enacted by the National Medical Products Administration (NMPA; Supplementary Table 1). Trained healthcare workers reviewed the returned diary cards for completeness and accuracy. Investigators with relevant qualifications would determine the causality of adverse reactions/events according to the implementation rules (Supplementary Table 2), which would be reviewed again by the Data and Safety Monitoring Board (DSMB) independent of the clinical trials to confirm the correlation between adverse reactions/events and the vaccines. The correlation was classified as positive correlation, high probability correlation, possible correlation, possible irrelevance and irrelevance (with the first three categories considered vaccine related).

Immunogenicity assessments

Serum samples were collected at day 0 and month 7 for all the participants to quantitatively measure IgG antibodies as described previously [21–23]. IgG antibodies against HPV-16, HPV-18 and HEV were quantified using references traceable to the WHO standards for antibodies against HPV-16 (NIBSC code 05/134), HPV-18 (NIBSC code 10/140) and HEV (NIBSC code 95/584), respectively. The lower detection limits of the assays were 3.1 IU/ml for HPV-16 antibodies, 2.0 IU/ml for HPV-18 antibodies and 0.077 Wu/ml for HEV antibodies. Antibody titers below the lower
detection limit of the assay were given an arbitrary value of half the cutoff value for calculating the geometric mean concentration (GMC).

**Statistical analysis**

This post hoc analysis of safety and immunogenicity was performed on participants who complied with the protocol, received 3 doses of vaccine within the requested time window, were negative for the corresponding antibody at entry, and had IgG antibody results at month 7. We assessed the relationship between inflammation-related solicited adverse reactions (ISARs) during days 0–7 postvaccination and GMC of IgG antibodies. Covariance (ANCOVA) analysis was performed to compare the GMC based on whether there was pain, induration, redness, swelling at the injection site or fever, which were generally considered to be more typical symptoms of inflammation in the immune response.

We subsequently attempted to set up a calculating method to quantify the inflammatory response based on the data of Cecolin®. Each symptom and different level of severity were given a weight coefficient (determined by GMC ratio). Each individual in the data set (DS) had a score of inflammation-related solicited adverse reactions (SI) that was defined by:

$$SI = \sum (W_{i,j} \cdot W_s)$$

where $W_{i,j}$ and $W_s$ are the weight coefficients of a certain symptom $i$ ($i =$ pain or induration or redness or swelling or fever) after dose $j$ ($j = 1, 2, 3$) and level of severity ($s = 1, 2, 3$), respectively. Thus, each ISAR with a certain level of severity occurring after any dose would be counted in the score. ANCOVA was then also used to compare the levels of antibodies in different groups of SI.

**Results**

**A tentative exploration**

We used the phase III trial of Cecolin® as our preliminary exploratory study. A total of 2302 and 2802 participants were included in the DS for HPV-16 and 18, respectively (Figure 1). Approximately 58.1% (1338/2302) and 58.6% (1642/2802) of the women in the HPV-16 and HPV-18 DS, respectively, reported at least one ISAR; among them, approximately 39.8% (532/1338) and 39.4% (647/1642) experienced ISAR after two or more injections, and most of the reactions were mild with grade 1 or grade 2.

Pain at the injection site (34.8% in the DS-HPV-16; 34.5% in the DS-HPV-18) and fever (35.2% in the DS-HPV-16; 35.6% in the DS-HPV-18) were the two most common solicited adverse reactions. On covariance analysis (Table 1), the GMCs for anti-HPV-16 and 18 IgG were significantly higher in women who had ISAR following vaccination than in those who had no ISARs (HPV16: 841.6 IU/ml [95% CI 810.0–874.4] vs 724.5 IU/ml [95% CI 692.6–757.9], $P_{16} < 0.001$; HPV18: 279.5 IU/ml [95% CI 269.4–290.0] vs 252.2 IU/ml [95% CI 241.4–263.5], $P_{18} < 0.001$). Also, the incidence of ISAR was higher in women with higher titer of antibodies after vaccination (Supplementary Figure 1). A relatively larger proportion of women aged 18–26 years had ISARs than women aged 27–45 years (63.6% vs 53.1%, Table 1), accompanied by higher antibody GMCs in women aged 18–26 years than in women aged 27–45 years. The limited available immuno-persistence data showed that the correlation of ISAR incidence with long-term IgG antibody levels (at month 18, 30 and 42m) showed similar

---

Figure 1. Flowchart of the studies.
| ISAR            | n (%) | median age (interquartile range) | IgG GMC (95% CI) | P   | n (%) | median age (interquartile range) | IgG GMC (95% CI) | P   |
|-----------------|-------|-------------------------------|------------------|-----|-------|-------------------------------|------------------|-----|
| any ISAR        |       |                               |                  |     |       |                               |                  |     |
| No              | 964 (41.9%) | 30.5 (25.39) | 724.5 (692.6, 757.9) | <0.001 | 1160 (41.4%) | 30 (25.39) | 252.2 (241.4, 263.5) | <0.001 |
| Yes             | 1338 (58.1%) | 26 (24.35) | 841.6 (810.0, 874.4) |       | 1642 (58.6%) | 26 (24.35) | 279.5 (269.4, 290.0) |       |
| 18–26 y         |       |                               |                  |     |       |                               |                  |     |
| No              | 400 (36.4%) | 24 (23.25) | 858.8 (800.6, 921.2) | 0.057 | 489 (36.1%) | 24 (23.25) | 292.9 (273.8, 313.4) | 0.415 |
| Yes             | 700 (63.6%) | 24 (23.25) | 935.4 (887.1, 986.3) |       | 866 (63.9%) | 24 (23.25) | 303.4 (288.4, 319.2) |       |
| 27–45 y         |       |                               |                  |     |       |                               |                  |     |
| No              | 564 (46.9%) | 38 (33.42) | 642.2 (606.5, 680.0) | <0.001 | 671 (46.4%) | 38 (33.41) | 226.2 (213.8, 239.3) | 0.002 |
| Yes             | 638 (53.1%) | 35 (31.40) | 749.4 (710.2, 790.8) |       | 776 (53.6%) | 36 (31.40) | 255.1 (242.1, 268.8) |       |
| Maximum severity|       |                               |                  |     |       |                               |                  |     |
| grade 1 or 2    | 1317 (98.4%) | 26 (24.35) | 837.4 (805.6, 870.5) | 0.047 | 1612 (98.2%) | 26 (24.35) | 278.0 (267.8, 288.7) | 0.037 |
| grade 3         | 21 (1.6%) | 26 (23.33) | 1145.5 (842.7, 1557.2) |       | 30 (1.8%) | 25 (23.33) | 373.8 (283.8, 492.3) |       |
| The number of injections resulting in ISARs |       |                               |                  |     |       |                               |                  |     |
| 1               | 806 (60.2%) | 27 (24.36) | 809.7 (770.6, 850.8) | 0.023 | 995 (60.6%) | 27 (24.36) | 275.3 (262.4, 288.8) | 0.524 |
| 2               | 405 (30.3%) | 26 (24.33) | 872.3 (813.5, 935.4) |       | 497 (30.3%) | 26 (24.34) | 283.5 (264.9, 303.4) |       |
| 3               | 127 (9.5%) | 26 (24.31) | 958.8 (846.4, 1086.2) |       | 150 (9.1%) | 26 (24.31) | 295.0 (260.3, 333.8) |       |
| Pain            |       |                               |                  |     |       |                               |                  |     |
| No              | 1501 (65.2%) | 28 (24.38) | 766.2 (739.0, 794.5) | 0.004 | 1835 (65.5%) | 28 (24.38) | 258.6 (249.8, 267.8) | 0.001 |
| Yes             | 801 (34.8%) | 26 (24.35) | 837.7 (797.1, 880.3) |       | 967 (34.5%) | 26 (24.35) | 286.4 (273.0, 300.5) |       |
| Induration      |       |                               |                  |     |       |                               |                  |     |
| No              | 2137 (92.8%) | 27 (24.37) | 785.9 (760.4, 808.1) | 0.047 | 2594 (92.6%) | 27 (24.37) | 266.1 (258.4, 274.0) | 0.097 |
| Yes             | 165 (7.2%) | 26 (24.36) | 879.5 (883.8, 981.3) | 0.047 | 208 (7.4%) | 26 (24.36) | 291.5 (262.3, 323.2) |       |
| Redness         |       |                               |                  |     |       |                               |                  |     |
| No              | 2197 (95.4%) | 27 (24.37) | 787.0 (763.8, 811.0) | 0.193 | 2679 (95.6%) | 27 (24.37) | 266.8 (259.2, 274.6) | 0.172 |
| Yes             | 105 (4.6%) | 29 (25.38) | 864.0 (753.2, 991.2) |       | 123 (4.4%) | 28 (25.38) | 293.6 (256.6, 335.9) |       |
| Swelling        |       |                               |                  |     |       |                               |                  |     |
| No              | 2193 (95.3%) | 27 (24.37) | 782.6 (759.4, 806.4) | 0.003 | 2675 (95.5%) | 27 (24.37) | 264.8 (257.3, 272.6) | <0.001 |
| Yes             | 109 (4.7%) | 29 (25.39) | 965.6 (844.0, 1104.7) |       | 127 (4.5%) | 27 (24.39) | 340.8 (298.6, 388.9) |       |
| Fever           |       |                               |                  |     |       |                               |                  |     |
| No              | 1492 (64.8%) | 29 (25.39) | 761.1 (734.0, 789.3) | 0.001 | 1804 (64.4%) | 29 (25.38) | 264.3 (251.2, 273.8) | 0.212 |
| Yes             | 810 (35.2%) | 26 (24.34) | 847.3 (806.5, 890.1) |       | 998 (35.6%) | 26 (24.34) | 274.4 (261.8, 287.7) |       |

ISAR, inflammation-related solicited adverse reaction; N, the total sample size; n, the number of participants; CI, confidence interval; GMC, geometric mean concentration.
trends, although significant difference was presented only in the DS for HPV-18 (Supplementary Table 3).

Higher GMCs for anti-HPV-16 and 18 IgG were recorded in women who experienced grade 3 ISAR, and lower GMCs were recorded in those who experienced grade 1 or 2 ISAR (HPV16: 1145.5 IU/ml [95% CI 842.7–1557.2], $P_{16} = 0.047$; HPV18: 373.8 IU/ml [95% CI 283.8–492.3] vs 278.0 IU/ml [95% CI 267.8–288.7], $P_{18} = 0.037$). With the increasing number of injections resulting in ISARs, there was an upward trend in GMCs, although a significant difference was only noted in GMCs for anti-HPV-16 ($P_{16} = 0.023$). When ISAR was subdivided into five symptoms, we found that there was a trend towards higher GMCs in women with any one of the symptoms overall. Significant differences were observed in both HPV types IgG between women with and without pain ($P_{16} = 0.004$; $P_{18} = 0.001$) or swelling ($P_{16} = 0.003$; $P_{18} < 0.001$) at the injection site, as well as anti-HPV-16 IgG between women with and without induration at the injection site ($P_{16} = 0.047$) or fever ($P_{16} = 0.001$).

Validation and further analysis

Similar findings with significantly higher GMCs in individuals who had ISAR following vaccination were revealed by the analysis of the bridging study of Cecolin® (Table 2, Supplementary Figure 1) and the phase III trial of the HEV vaccine (Table 3, Supplementary Figure 1). In the DS of the bridging study, GMCs of IgG against HPV-16 were significantly higher in girls or young women who experienced ISARs versus no ISARs (2537.0 IU/ml [95% CI 2338.0–2752.8] vs 2057.3 IU/ml [95% CI 1882.3–2248.5], $P_{16} = 0.001$). Men and women with ISARs had significantly higher GMCs for anti-HEV IgG than those without ISARs in the DS of the phase III trial of HEV vaccine (21.38 WU/ml [95% CI 18.86–24.23] vs 16.74 WU/ml [95% CI 15.31–18.29], $P_{HEV} = 0.002$). No obvious increasing trend was observed on GMCs in increasing severity or number of injections resulting in ISARs. Significant differences were observed in GMCs for anti-HPV-16 and anti-HEV IgG between subjects with fever and those without fever (HPV16: 2613.9 IU/ml [95% CI 2357.4–2898.3] vs 2159.8 IU/ml [95% CI 2005.2–2326.3], $P_{16} = 0.003$; HEV: 21.06 WU/ml [95% CI 18.09–24.52] vs 17.38 WU/ml [95% CI 15.99–18.89], $P_{HEV} = 0.030$).

Quantitative model

Based on the results from the analysis of the phase III trial and the bridging study of Cecolin®, we used the GMC ratio as the weight coefficients (Table 4) and obtained a SI at the individual level. According to the model, the SI of subjects who never experienced an ISAR following vaccination was 0, while subjects with any ISAR had a SI between 1.00 and 12.44 in the DS of HPV-16 and 1.00 and 11.34 in the DS of HPV-18. As shown in Figure 2, there were nonlinear curves between the SI and GMCs, and the GMCs tended to be higher as the SI increased to a certain level.

Discussion

To our knowledge, this is the first study to systematically analyze the correlation between inflammation-related solicited adverse reactions and specific immune responses induced by vaccines in humans with a large sample size. In the phase III trial of Cecolin®, we observed significantly higher GMCs for anti-HPV-16 and -18 in vaccinees who had ISARs compared with those without ISARs. For each of the five ISAR symptoms, there was a trend towards higher GMCs for anti-HPV-16 and/or -18 in women with pain, induration, redness, or swelling at the injection site or fever compared with those without the relative symptom, although some differences were not significant. The findings were validated by data from another two clinical trials of recombinant vaccines.

The prerequisite for eliciting immune responses is to provide sufficient “danger signals” by triggering an inflammatory reaction mediated by cells of the innate immune system [30–33], which followed a complex series of innate immune events, such as phagocytosis, release of inflammatory mediators including chemokines and cytokines, activation of complement, liberation of vasodilators and cellular recruitment [30–34]. Vasodilators and the chemokine gradient facilitate cell recruitment from blood but also lead to the development of redness and swelling at the injection site [13]. When vaccines, especially adjuvanted vaccines, cannot be absorbed in a timely fashion and thus remain at the injection site, induration at the injection site can occur due to a prolonged inflammatory response [35]. Induration is a special manifestation of acute inflammation due to the local extravasation and attraction of immune cells in response to long-living “foreign matter”. Besides, immune cells may initiate the sensitization of peripheral nociceptors by releasing soluble factors, such as cytokines, prostaglandins or ATP, and interactions with neurotransmitters and their receptors [36]. Recent studies [37,38] have shown an important role of the sensory nervous system in mechanisms controlling antigen-specific antibody responses. In our study, pain at the injection site is also considered to be highly correlated with higher antibody levels following HPV vaccination.

Meanwhile, mediators and products of inflammation in the circulation may affect other body systems or organs to cause systemic adverse reactions
Table 2. Antibody levels of HPV-16 and -18 IgG in the presence of different ISAR (a bridging study of Cecolin®).

| ISAR   | n(%)       | median age (Interquartile range) | IgG GMC(95%CI) | P     | n(%)       | median age (Interquartile range) | IgG GMC(95%CI) | P     |
|--------|------------|---------------------------------|----------------|-------|------------|---------------------------------|----------------|-------|
| any ISAR |            |                                 |                |       |            |                                 |                |       |
| No     | 243 (45.8%)| 15 (12,21)                      | 2057.3 (1882.3,2248.5) | 0.001 | 261 (46.0%)| 15 (12,21)                      | 501.8 (454.4,554.1) | 0.094 |
| Yes    | 288 (54.2%)| 15 (12,19)                      | 2537.0 (2338.0,2752.8) |       | 306 (54.0%)| 15 (11,19)                      | 563.2 (513.9,617.3) |       |
| 9-16y  |            |                                 |                |       |            |                                 |                |       |
| No     | 163 (44.5%)| 13 (11,15)                      | 2508.9 (2269.1,2773.9) | 0.017 | 172 (44.2%)| 13 (11,15)                      | 655.8 (583.6,736.9) | 0.981 |
| Yes    | 203 (55.5%)| 13 (11,15)                      | 2957.8 (2703.2,3323.3) |       | 217 (55.8%)| 13 (10,15)                      | 657.0 (592.2,728.9) |       |
| 18-26y |            |                                 |                |       |            |                                 |                |       |
| No     | 80 (48.5%) | 23 (21,25)                      | 1373.1 (1184.9,1591.2) | 0.019 | 89 (50%)   | 23 (21,25)                      | 299.1 (257.9,346.9) | 0.016 |
| Yes    | 85 (51.5%) | 22 (20,25)                      | 1758.4 (1524.1,2028.9) |       | 89 (50%)   | 23 (20,25)                      | 386.8 (333.5,448.6) |       |
| Maximum severity |            |                                 |                |       |            |                                 |                |       |
| grade 1 or 2 |          |                                 |                |       |            |                                 |                |       |
| No     | 282 (97.9%)| 15 (12,19)                      | 2546.5 (2338.2,2773.3) | 0.547 | 300 (98.0%)| 15 (12,19)                      | 556.8 (508.7,609.4) | 0.075 |
| Yes    | 6 (2.1%)   | 12.5 (9,16)                     | 2124.4 (1183.7,3812.7) |       | 6 (2.0%)   | 13.5 (9,23)                     | 1000.4 (528.2,1894.9) |       |
| grade 3 |            |                                 |                |       |            |                                 |                |       |
| Pain   |            |                                 |                |       |            |                                 |                |       |
| No     | 395 (74.4%)| 15 (11,19)                      | 2281.3 (2126.1,2447.8) | 0.570 | 415 (73.2%)| 15 (11,19.5)| 531.0 (490.7,574.6) | 0.783 |
| Yes    | 136 (25.6%)| 15 (13,20.5)                    | 2375.0 (2106.3,2678.0) |       | 152 (26.8%)| 16 (13,21)                     | 542.5 (476.2,618.0) |       |
| Induration |            |                                 |                |       |            |                                 |                |       |
| No     | 503 (94.7%)| 15 (12,19.5)                    | 2298.8 (2159.6,2446.9) | 0.714 | 535 (94.4%)| 15 (11,20)                      | 535.2 (499.3,573.8) | 0.790 |
| Yes    | 28 (5.3%)  | 16 (14,22)                      | 2418.5 (1856.0,3151.9) |       | 32 (5.6%)  | 17 (14,23)                      | 514.4 (387.1,683.4) |       |
| Redness |            |                                 |                |       |            |                                 |                |       |
| No     | 508 (95.7%)| 15 (12,20)                      | 2290.0 (2152.1,2436.7) | 0.322 | 543 (95.8%)| 15 (12,20)                      | 531.7 (496.3,569.7) | 0.545 |
| Yes    | 23 (4.3%)  | 16 (13.5,21.5)                  | 2662.1 (1988.3,3564.1) |       | 24 (4.2%)  | 16.5 (14.5,22.5)                | 589.5 (424.7,781.8) |       |
| Swelling |          |                                 |                |       |            |                                 |                |       |
| No     | 502 (94.5%)| 15 (12,20)                      | 2276.5 (2138.9,2423.0) | 0.095 | 536 (94.5%)| 15 (12,20)                      | 528.1 (492.8,566.0) | 0.178 |
| Yes    | 29 (5.5%)  | 16 (15,21)                      | 2857.8 (2204.8,3704.3) |       | 31 (5.5%)  | 16 (14,21.5)                    | 647.4 (485.3,863.7) |       |
| Fever  |            |                                 |                |       |            |                                 |                |       |
| No     | 350 (65.9%)| 15 (12,21)                      | 2159.8 (2005.2,2326.3) | 0.003 | 372 (65.6%)| 15 (12,21)                      | 512.7 (471.8,557.2) | 0.102 |
| Yes    | 181 (34.1%)| 14 (11,17)                      | 2613.9 (2357.4,2898.3) |       | 195 (34.4%)| 14 (11,17)                      | 577.2 (514.6,647.4) |       |

ISAR, inflammation-related solicited adverse reaction; N, the total sample size; n, the number of participants; CI, confidence interval; GMC, geometric mean concentration.
such as fever [13]. The fact that fever promotes the immune response has been validated by numerous studies [17–19]. However, as a typical manifestation of inflammatory responses, fever can be caused by a number of complex factors and can also be treated with physical or pharmaceutical interventions, which may be some of the reasons that make it more difficult to find a strong correlation between fever and antibodies induced by vaccines in the real world. A meta-analysis concluded that while prophylactic antipyretics significantly reduced injection-site and systemic symptoms in children after vaccination, their use was associated with reduced antibody responses to most vaccines. However, whether antipyretic interventions before or after vaccination do more harm than good cannot be answered before more clinical evidence is obtained.

Table 1 shows that the median age of people with ISARs was younger than those without ISARs, a relatively larger proportion of women aged 18–26 years had ISARs than women aged 27–45 years, and the older the age, the lower the incidence of ISARs and the weaker the immune response. Undoubtedly, age is an important factor in influencing reactogenicity in light of physiological functions of the immune and nervous systems that evolve throughout life, including the susceptibility to adverse reactions to vaccination. Fewer reported ISARs in relatively older people is possibly due to higher tolerance to pain or the waning of innate immune defense mechanisms [39], which was supported by the results of a study [40] that older people display lower systemic levels of IL-6, IL-10 and C-reactive protein (CRP) after vaccination. At the same time, it has become evident that young people tend to gain higher antibody levels after vaccination [41]. Hence, the factor of age, to a certain extent, explains the inevitable connection between immunogenicity and adverse reactions from the perspective of the individual characteristics. Moreover, according to the results of age-stratified analysis shown in Tables 1–3, it seems that the positive

Table 3. Antibody levels of HEV in the presence of different ISAR (a phase III trial of HEV vaccine).

| ISAR            | n(%)       | Gender ratio* (male: female) | Median age (interquartile range) | Anti-HEV IgG GMC(95%CI) | P      |
|-----------------|------------|-----------------------------|----------------------------------|-------------------------|--------|
| Any ISAR        |            |                             |                                  |                         |        |
| No              | 293 (66.6%)| 103: 190                    | 42 (35,52)                       | 16.74 (15.31,18.29)     | 0.002  |
| Yes             | 147 (33.4%)| 27: 120                     | 41 (36,48.5)                     | 21.38 (18.86,24.23)     |        |
| 16-40y ISAR     |            |                             |                                  |                         |        |
| No              | 129 (66.2%)| 43: 86                      | 32 (27,37)                       | 18.35 (16.11,20.91)     | 0.209  |
| Yes             | 66 (33.8%) | 13: 53                      | 35 (28,38)                       | 21.18 (17.65,25.43)     |        |
| 41-65y ISAR     |            |                             |                                  |                         |        |
| No              | 164 (66.9%)| 60: 104                     | 51 (47,57)                       | 15.57(13.79,17.58)      | 0.003  |
| Yes             | 81 (33.1%) | 14: 67                      | 48 (43,53)                       | 21.54(18.12,25.59)      |        |
| Maximum severity grade 1 or 2 | 145 (98.6%)| 27: 118                   | 41 (36,49)                       | 21.76 (19.44,24.36)     | -      |
| grade 3         | 2 (1.4%)   | 0: 2                        | 33.5 (24,43)                     | 5.85 (2.24,15.28)       |        |
| The number of injections occurring ISAR |      |                             |                                  |                         |        |
| 1               | 112 (76.2%)| 23: 89                      | 41.5 (36,49)                     | 20.73 (18.18,23.65)     | 0.643  |
| 2               | 27 (18.4%) | 3: 24                       | 43 (36,48)                       | 23.59 (18.05,30.85)     |        |
| 3               | 8 (5.4%)   | 1: 7                        | 38 (36,39.5)                     | 23.51 (14.37,38.47)     |        |
| Pain            |            |                             |                                  |                         |        |
| No              | 392 (89.1%)| 121: 271                    | 42 (35,52)                       | 17.80 (16.47,19.23)     | 0.117  |
| Yes             | 48 (10.9%) | 9: 39                       | 41 (35,54,8)                     | 21.46 (17.20,26.78)     |        |
| Induration      |            |                             |                                  |                         |        |
| No              | 434 (98.6%)| 128: 306                    | 42 (35,51)                       | 18.09 (16.80,19.47)     | 0.356  |
| Yes             | 6 (1.4%)   | 2: 4                        | 39 (35,49)                       | 24.34 (13.00,45.57)     |        |
| Redness         |            |                             |                                  |                         |        |
| No              | 435 (98.9%)| 130: 305                    | 42 (35,51)                       | 18.09 (16.81,19.47)     | 0.317  |
| Yes             | 5 (1.1%)   | 0: 5                        | 44 (40,54)                       | 25.73 (12.95,51.14)     |        |
| Swelling        |            |                             |                                  |                         |        |
| No              | 427 (97.0%)| 130:297                     | 42 (35,51)                       | 17.96 (16.68,19.35)     | 0.089  |
| Yes             | 13 (3.0%)  | 0: 13                       | 40 (38,43)                       | 26.13 (17.08,39.97)     |        |
| Fever           |            |                             |                                  |                         |        |
| No              | 339 (77.0%)| 109: 230                    | 42 (35,51)                       | 17.38 (15.99,18.89)     | 0.030  |
| Yes             | 101 (23.0%)| 21: 80                      | 41 (37,51)                       | 21.06 (18.09,24.52)     |        |

ISAR, inflammation-related solicited adverse reaction; N, the total sample size; n, the number of participants; CI, confidence interval; GMC, geometric mean concentration; NA, not applicable.

* There was no significant difference in antibody levels between the females and the males (P=0.147).

Table 4. Weight coefficient*.

| ISAR      | HPV16 | HPV18 |
|-----------|-------|-------|
| Severity (Ws) |       |       |
| 1 or 2    | 1.16  | 1.10  |
| 3         | 1.58  | 1.48  |
| Symptoms (Wi) |       |       |
| Pain      | 1.09  | 1.11  |
| Induration| 1.12  | 1.10  |
| Redness   | 1.10  | 1.10  |
| Swelling  | 1.23  | 1.29  |
| Fever     | 1.11  | 1.04  |

ISAR: inflammation-related solicited adverse reaction; Ws: the weight coefficient of severity; Wi: the weight coefficient of symptoms.

* Weight coefficients are derived from the ratio of geometric mean concentrations (GMCs) for antibodies. For example, the weight coefficient of “pain” is calculated by the ratio of GMCs for antibodies of vaccinees with pain to that of vaccinees without pain.
correlations between ISAR and IgG antibodies are more pronounced in the older age groups than that in the younger age groups, which suggest that age might also be a potential influencing factor on the correlation of reactogenicity with adaptive immune response.

Equally important, as immunostimulants, adjuvants enhance the immune response to the antigen and usually increase reactogenicity [42,43]. The HPV-16/18 bivalent vaccine Cervarix® (GlaxoSmithKline, GSK) formulated by virus-like particles of the L1 protein and the Adjuvant System 04 (AS04), which is a combination of monophosphoryl lipid A (MPL) and aluminum salts, has shown good immunogenicity in clinical studies [44–46]. MPL is a specific agonist of TLR4 (Toll-like receptor), which is a kind of innate receptor (pattern recognition receptor, PRR) that can recognize conserved motifs expressed by microbes. Stimulation of TLR4 mimics the existence of “danger” [47]. Previous studies [48] on the mechanism of action of AS04 provided evidence that MPL enhances humoral and cell-mediated responses by rapidly triggering a local and transient cytokine response that leads to an increased activation of APCs and induces an improved presentation of antigen to CD4+ T cells, which can explain the higher levels of cytokines at the injection site [49] and the higher immunogenicity [50] of the AS04-adjuvanted vaccine compared with aluminum salt-based vaccines. However, a comparative study [51,52] on the immunogenicity and safety between Cervarix® and Gardasil® (HPV6/11/16/18: MSD, USA) suggested a higher incidence of solicited symptoms (injection-site reactions being most common) following the vaccination of Cervarix®. The similar phenomenon is common in studies on other vaccines, for instance, glycoprotein E adjuvanted with AS01B for Shingrix® leads to high reactogenicity than that without adjuvant while it greatly enhances the cellular and humoral immunogenicity [53], and the results of the phase 1/2 clinical trial of a recombinant COVID-19 vaccine showed that the formulation with Matrix-M1 induced much higher neutralizing antibody than that without adjuvant accompanied with more ISARs [54]. All these data further illustrated that inflammation induced by vaccines and their clinical manifestations may enhance the production of specific antibodies.

It is interesting to note that the severity and the number of injections resulting in ISARs also appear to be influencing factors for the levels of antibodies, according to the results of the phase III trial of Cecolin®. To our knowledge, such an impact of the severity and frequency of adverse reactions on antibody production has not been documented before. However, this correlation is only shown significance in HPV-16 specific antibody response of the phase III trial. The possible reasons are as follows: (1) The effect of the number of injections on the immune response is indeed very small or even negligible, it is due to other unknown confounding factors that cause a significant correlation in HPV-16 specific antibody response of the phase III trial. (2) The quantitative results of immunogenicity induced by different antigens or different reagents are incomparable. The discrimination between different antibody levels induced by the vaccine’s components of HPV-18 might be inferior to that of HPV-16, which could reduce the power of statistical analysis. The significant correlation is hard to show in overall lower antibody levels. (3) The limited sample size of the bridging study of Cecolin® and the phase III trial of HEV vaccine.

We also built a scoring model to assess ISARs following vaccination. The parameters of the model are derived from the ratio of GMCS for antibodies,
considering five typical symptoms of ISARs and the levels of severity of each ISAR. SI shows a similar exponential relation to GMCs for anti-HPV-16 and 18 IgG in the phase III trial of Cecolin®. This indicates that there are differences in the levels of antibodies between vaccinees with a SI below 6 and those with a SI of 6 or higher. However, the reason for the curve relationship is hard to explain because of the limited sample size of the high SI group in the present study. Notwithstanding that the quantitative model presented here is of limited clinical value, more important is the assumption of a quantifiable inflammatory response following vaccination. Although we know that an effective adaptive immune response requires a certain level of inflammation to be triggered [55], how to build a proper model and how to choose the most reliable symptoms or indicators to quantify the inflammatory level warrant further study.

Vaccine-induced immune effectors are essentially antibodies produced by B lymphocytes that can bind specifically to a toxin or a pathogen. The above-mentioned improved innate immune system accompanied with more severe ISAR would promote the antigen presentation by antigen-presenting cell (APC) and stimulate T cell-dependent B cell differentiation into antibody-secreting cells and memory B cells. From the results in Supplementary Table 3, we also found that the long-term IgG antibody against HPV-18 is significantly correlated with ISAR, which may be largely related to the role of memory B cells.

Currently, vaccines have largely been developed empirically, with limited knowledge of how exactly they activate the immune system [8], let alone the extent to which adverse reactions are caused by the reactogenicity of vaccines. Since the beneficial effects of vaccines are a result of changes in the immune system, it would not be surprising if some of the adverse reactions were also. Thus, more studies are needed to understand adverse reactions following vaccination. One approach is to observe and study adverse reactions during clinical trials to explore which adverse reactions are predictive of improved immunization outcomes. Indeed, the development of vaccines should appropriately focus on this aspect and not only on the avoidance of adverse reactions. There is uncertainty regarding whether our findings on ISARs and immunogenicity translate into clinically meaningful effects. However, these results can change people’s perception of adverse reactions following vaccination and may be a powerful weapon in the fight against vaccine hesitancy.

The limitations of this study include that only data of recombinant, adjuvanted vaccines are analyzed. The extent to which antigens and adjuvants contribute to reactogenicity in addition to other baseline physiological characteristics (such as body mass index, circadian cycle, psychological stress, etc) needs to be further confirmed and also through similar studies on other types of vaccines (live/nonlive/nonadjuvanted). And both the HPV (Cecolin®) and HEV (Hecolin®) vaccines investigated in this study showed efficacy of 100% in the phase 3 clinical trial against clinical endpoints, thus they are not the proper data sets for analyzing the relationship between ISAR and protection, the correlation between ISARs and the actual efficacy of vaccines is worthy of further study in the future and has practical significance.

In conclusion, this study suggests inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. However, because of incomplete knowledge about the biological mechanisms of vaccine-induced injury and the immune response process, the clinical relevance of these immunological findings warrants further assessment.

Acknowledgement
The authors thank all participants in the study.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This work was supported by the National Natural Science Foundation [grant number 81991491]; the Joint Funds for the Health Education, Fujian province [grant number 2019-WJ-05]; CAMS Innovation Fund for Medical Sciences [grant number 2019RU022]; National Key Projects in Science and Technology [grant number 2018ZX09303005-002].

Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Ning-Shao Xia  http://orcid.org/0000-0003-0179-5266

References
[1] Gilbert NL, Gilmour H, Dube E, et al. Estimates and determinants of HPV non-vaccination and vaccine refusal in girls 12 to 14 y of age in Canada: results from the Childhood National Immunization Coverage Survey, 2013. Hum Vaccin Immunother. 2016;12(6):1484–1490. DOI:10.1080/21645515.2016.1153207
[2] Gilkey MB, Calo WA, Marcinik MW, et al. Parents who refuse or delay HPV vaccine: differences in vaccination behavior, beliefs, and clinical communication
preferences. Hum Vaccin Immunother. 2017;13 (3):680–686. DOI: 10.1080/21645515.2016.1247134

[3] Simms KT, Hanley SB, Smith MA, et al. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020. DOI: 10.1016/s2468-2667(20)30010-4

[4] Lo Vecchio A, Cambrigia MD, Fedele MC, et al. Determinants of low measles vaccination coverage in children living in an endemic area. Eur J Pediatr. 2019;178(2):243–251. DOI: 10.1007/s00431-018-3289-5

[5] Quinn SC, Jamison AM, Freimuth VS. Measles outbreaks and public attitudes towards vaccine exemptions: some cautions and strategies for addressing vaccine hesitancy. Hum Vaccin Immunother. 2020;16(5):1050–1054. DOI: 10.1080/21645515.2019.1646578

[6] Mulligan MJ, Lyke KE, Kitchin N, et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: Interim report. medRxiv Preprint. 2020. DOI: 10.1101/2020.06.30.20142570

[7] Walsh EE, Frenck R, Falsely AR, et al. RNA-Based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv Preprint. 2020. DOI: 10.1101/2020.08.17.20176651

[8] Plotkin SA, Orenstein WA, Offit PA, Edwards KM. Vaccine. 7th ed. Philadelphia, PA: Elsevier; 2018.

[9] Vetter V, Denizer G, Friedland LR, et al. Vaccination of a randomized clinical trial. J Natl Cancer Inst. 2015;107(23):2265–2266. DOI: 10.1093/jnci/djv074

[10] Nakayama T. An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity. Vaccine. 2016;34 (47):5815–5818. DOI: 10.1016/j.vaccine.2016.08.051

[11] Garly M-L, Martins CI, Balé C, et al. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. Vaccine. 2003;21(21-22):2782–2790. DOI: 10.1016/s0264-410x(03)00181-6

[12] Roth A, Gustafson P, Ngaha A, et al. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol. 2005;34(3):540–547. DOI: 10.1093/ije/dyh392

[13] Herve C, Laupeze B, Del Giudice G, et al. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4:39. DOI: 10.1038/s41541-019-0132-6

[14] Vaccine Safety Committee IoM. Adverse events associated with childhood vaccines: evidence bearing on causality. In: Stratton KR, Howe CJ, Johnston RB, Jr., editors. Adverse events associated with childhood vaccines: evidence bearing on causality. The National academies collection: reports funded by National Institutes of Health. Washington (DC): National Academies Press (US); 1994. p. 059–062.

[15] Spencer JP, Tronsden Pawlowski RH, Thomas S. Vaccine adverse events: separating myth from reality. Am Fam Physician. 2017;95(12):786–794.

[16] Chandler RE, Juhl K, Fransson J, et al. Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase(R). Drug Saf. 2017;40(1):81–90. DOI: 10.1007/s40264-016-0456-3

[17] Hasday JD, Garrison A, Singh IS, et al. Febrile-range hyperthermia augments pulmonary neutrophil recruitment and amplifies pulmonary oxygen toxicity. Am J Pathol. 2003;162(6):2005–2017. DOI: 10.1016/s0002-9440(10)6433-7

[18] Ostberg JR, Patel R, Repasky EA. Regulation of immune activity by mild (fever-range) whole body hyperthermia: effects on epidermal langerhans cells. Cell Stress Chaperones. 2000;5(5):458–461. DOI: 10.1379/1466-1268(2000)005<0458:roabm2.0.co;2

[19] Lin C, Zhang Y, Zhang K, et al. Fever promotes T lymphocyte trafficking via a thermal sensory pathway involving heat shock protein 90 and alpha4 integrins. Immunity. 2019;50(1):137–136. DOI: 10.1016/j.immuni.2018.11.013

[20] Nakayama T. Causal relationship between immunological responses and adverse reactions following vaccination. Vaccine. 2019;37(2):366–371. DOI: 10.1016/j.vaccine.2018.11.045

[21] Qiao YL, Wu T, Li RC, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst. 2020;112(2):145–153. DOI: 10.1093/jnci/djy074

[22] Hu Y, Guo M, Li C, et al. Immunogenicity and safety of a recombinant hepatitis E vaccine in girls vs. 3 doses in young women. Sci China Life Sci. 2019. DOI: 10.1007/s11427-019-9547-7

[23] Zhu F-C, Zhang J, Zhang X-F, et al. Vaccination of a randomized clinical trial. J Natl Cancer Inst. 2015;107(23):2265–2266. DOI: 10.1093/jnci/djv074

[24] Hu YM, Huang SJ, Chu K, et al. Safety of an Escherichia coli-expressed bivalent human papillomavirus vaccine (types 16 and 18) L1 virus-like particle vaccine: a random-label phase I clinical trial. Hum Vaccin Immunother. 2014;10(2):469–475. DOI: 10.4161/hv.26846

[25] Wu T, Hu YM, Li J, et al. Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus vaccine (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial. Vaccine. 2015;33(32):3940–3946. DOI: 10.1016/j.vaccine.2015.06.052

[26] Gu Y, Wei M, Wang D, et al. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Vaccine. 2017;35(35 Pt B):4637–4645. DOI: 10.1016/j.vaccine.2017.06.084

[27] Zhang J, Liu CB, Li RC, et al. Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine. 2009;27(12):1869–1874. DOI: 10.1016/j.vaccine.2008.12.061

[28] Li SW, Zhang J, Li YM, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine. 2005;23(22):2893–2901. DOI: 10.1016/j.vaccine.2004.11.064

[29] Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunology. 2010;33(4):492–503. DOI: 10.1016/j.immuni.2010.10.002

[30] Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15(2):51–57. DOI: 10.1101/in.2015.15.2.51

[31] O’Hagan DT, Fox CB. New generation adjuvants--from empiricism to rational design. Vaccine. 2015;33 (Suppl 2):B14–B20. DOI: 10.1016/j.vaccine.2015.01.088
[33] Maisonneuve C, Bertholet S, Philpott DJ, et al. Unleashing the potential of NOD- and toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014;111(34):12294–12299. DOI:10.1073/pnas.1400478111

[34] Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science. 2010;327(5963):291–295. DOI:10.1126/science.1183021

[35] Beveridge MG, Polcari IC, Burns JL, et al. Local vaccine site reactions and contact allergy to aluminium. Pediatr Dermatol. 2012;29(1):68–72. DOI:10.1111/j.1525-1470.2011.01541.x

[36] Ren K, Dubner R. Interactions between the immune and nervous systems in pain. Nat Med. 2010;16(11):1267–1276. DOI:10.1038/nm.2234

[37] Tynan A, Tsaava T, Gunasekaran M, et al. Antibody responses to immunization require sensory neurons. bioRxiv. 2019. DOI:10.1101/860395

[38] Lai NY, Musser MA, Pinho-Ribeiro FA, et al. Gut-Innervating nociceptor neurons regulate peyer's patch microfold cells and SFB levels to mediate salmonella host defense. Cell. 2020;180(1):33–49e22. DOI:10.1016/j.cell.2019.11.014

[39] Chen WH, Kozlovsky BF, Effros RB, et al. Vaccination in the elderly: an immunological perspective. Trends Immunol. 2009;30(7):351–359. DOI:10.1016/j.it.2009.05.002

[40] Youssi ME, Mercier S, Breuilé D, et al. The inflammatory response to vaccination is altered in the elderly. Mech Ageing Dev. 2005;126(8):874–881. DOI:10.1016/j.mad.2005.03.008

[41] Chen Q, Zhao H, Yao X, et al. Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages. Vaccine. 2020. DOI:10.1016/j.vaccine.2020.07.030

[42] Stassinis J, Bollaerts K, Baay M, et al. A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children. Vaccine. 2016;34(6):714–722. DOI:10.1016/j.vaccine.2015.12.024

[43] Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018;39:14–21. DOI:10.1016/j.smim.2018.05.001

[44] Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16(10):1154–1168. DOI:10.1016/s1473-3099(16)30120-7

[45] Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother. 2012;8(3):390–397. DOI:10.4161/hv.18865

[46] Zhu FC, Hu SY, Hong Y, et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18–25 years: End-of-study results from a phase II/III, randomised, controlled trial. Cancer Med. 2019;8(14):6195–6211. DOI:10.1002/cam4.2399

[47] Garçon N, Morel S, Didierlaurent A, et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs. 2011;25(4):217–226. DOI:10.2165/11591760-000000000-00000

[48] Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24(33-34):5937–5949. DOI:10.1016/j.vaccine.2006.06.005

[49] Kashiwagi Y, Maeda M, Kawashima H, et al. Inflammatory responses following intramuscular and subcutaneous vaccination with aluminum-adjuvanted or non-adjuvanted vaccines. Vaccine. 2014;32(27):3393–3401. DOI:10.1016/j.vaccine.2014.04.018

[50] Garçon N. Preclinical development of AS04. Methods Mol Biol. 2010;626:15–27. DOI:10.1007/978-1-60761-585-9_2

[51] Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin. 2009;5(10):705–719. DOI:10.4161/hv.5.10.9518

[52] Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18–45 years. Hum Vaccin. 2011;7(12):1343–1358. DOI:10.4161/hv.7.12.18281

[53] Chilib R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J Infect Dis. 2013;208(12):1953–1961. DOI:10.1093/infdis/jit365

[54] Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–2322. DOI:10.1056/NEJMoa2026920

[55] Vaccines CiRAEo, Medicine Io. Adverse effects of vaccines: evidence and causality. Stratton K, Ford A, Rusch E, Clayton EW, editors. Washington (DC): National Academies Press (US) Copyright 2012 by the National Academy of Sciences. All rights reserved; 2011.